Clinical trial
A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- October 26, 2022
- Completion date
- September 1, 2027
- Enrollment
- 126 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.
anal cancer, carcinoma, non-small-cell lung, carcinoma, ovarian epithelial, carcinoma, renal cell, carcinoma, thymic, cutaneous melanoma, esophagogastric cancer, high microsatellite instability colorectal carcinoma, mesothelioma, nasopharyngeal carcinoma, squamous cell carcinoma of head and neck, triple negative breast neoplasms